anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Blood products form the cornerstone of contemporary hemorrhage control but are limited resources. Freeze-dried plasma (FDP), which contains coagulation factors, is a promising adjunct in hemostatic resuscitation. We explore the association between FDP alone or in combination with other blood products on 24-h mortality.
STUDY DESIGN AND METHODS: This is a secondary data analysis from a cross-sectional prospective observational multicenter study of adult trauma patients in the Western Cape of South Africa. We compare mortality among trauma patients at risk of hemorrhage in three treatment groups: Blood Products only, FDP + Blood Products, and FDP only. We apply inverse probability of treatment weighting and fit a multivariable Cox proportional hazards model to assess the hazard of 24-h mortality.
RESULTS: Four hundred and forty-eight patients were included, and 55 (12.2%) died within 24 h of hospital arrival. Compared to the Blood Products only group, we found no difference in 24-h mortality for the FDP + Blood Product group (p = .40) and a lower hazard of death for the FDP only group (hazard = 0.38; 95% CI, 0.15-1.00; p = .05). However, sensitivity analyses showed no difference in 24-h mortality across treatments in subgroups with moderate and severe shock, early blood product administration, and accounting for immortal time bias.
CONCLUSION: We found insufficient evidence to conclude there is a difference in relative 24-h mortality among trauma patients at risk for hemorrhage who received FDP alone, blood products alone, or blood products with FDP. There may be an adjunctive role for FDP in hemorrhagic shock resuscitation in settings with significantly restricted access to blood products.
The data presented below include references to peak steady-state plasma acyclovir concentrations observed in humans treated with 800mg given orally 5 times a day (dosing appropriate for treatment of herpes zoster) or 200mg given orally 5 times a day (dosing appropriate for treatment of genital herpes). Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir at the higher and lower dosing schedules (see CLINICAL PHARMACOLOGY: Pharmacokinetics).

Acyclovir was tested in lifetime bioassays in rats and mice at single daily doses of up to 450mg/kg administered by gavage. There was no statistically significant difference in the incidence of tumors between treated and control animals, nor did acyclovir shorten the latency of tumors. Maximum plasma concentrations were 3 to 6 times human levels in the mouse bioassay and 1 to 2 times human levels in the rat bioassay.

Acyclovir was tested in 16 in vitro and in vivo genetic toxicity assays. Acyclovir was positive in 5 of the assays.

Acyclovir did not impair fertility or reproduction in mice (450mg/kg/day, p.o.) or in rats (25mg/kg/day, s.c.). In the mouse study, plasma levels were 9 to 18 times human levels, while in the rat study, they were 8 to 15 times human levels. At higher doses (50mg/kg/day, s.c.) in rats and rabbits (11 to 22 and 16 to 31 times human levels, respectively) implantation efficacy, but not litter size, was decreased. In a rat peri- and post-natal study at 50mg/kg/day, s.c., there was a statistically significant decrease in group mean numbers of corpora lutea, total implantation sites, and live fetuses.

No testicular abnormalities were seen in dogs given 50mg/kg/day, IV for 1 month (21 to 41 times human levels) or in dogs given 60mg/kg/day orally for 1 year (6 to 12 times human levels). Testicular atrophy and aspermatogenesis were observed in rats and dogs at higher dose levels.
PCT No. PCT/AU91/00160 Sec. 371 Date Nov. 27, 1991 Sec. 102(e) Date Nov. 27, 1991 PCT Filed Apr. 24, 1991 PCT Pub. No. WO91/16010 PCT Pub. Date Oct. 31, 1991A composite living skin equivalent is described comprising an epidermal layer of cultured keratinocyte cells, a layer of non-porous collagen, and a dermal layer of cultured fibroblast cells in a porous cross-linked collagen sponge matrix. Preferably the non-porous collagen is Type 1, Type 3 or mixtures of Types 1 and 3 bovine collagen, which has been pepsin treated. A process for preparing the skin equivalent is described, as well as a test kit for in vitro testing of the skin equivalent. The skin equivalent has use for skin grafting as well as in vitro testing of the effects of various substances on skin. +RR The questions raised in reexamination request No. 90/003,418, filed Apr. 25, 1994, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).
PURPOSE: A natural hair cosmetic composition by maturing natural ingredients is provided to suppress inhabitation of demodicidosis. CONSTITUTION: A natural hair cosmetic composition contains 30-70 weight parts of henna extract; 15-60 weight parts of plant extract of ginkgo leaves, persimmon leaves, or Sasa borealis (Hack.) Makino leaves; 5-20 weight parts of mulberry leaf extract; 5-20 weight parts of egg; 5-20 weight parts of dairy products, and kelp water. The egg is matured in vinegar. The hair cosmetic composition further contains 0.005-0.5 weight parts of gold powder, 5-20 weight parts of collagen, or 5-20 weight parts of pomegranate. The hair cosmetic composition also contains mordant, coloring agent, disinfection antiseptic, adsorbing agent, or softening agent.
During June-August, 2015, approximately 500 women will be recruited at routine obstetric visits to the University of Michigan's outpatient clinics. Women who check in for an Ob appointment will be offered the opportunity to participate in an anonymous online survey. Individuals who express interest in participating will be provided with a laptop and headphones and directed to the survey Qualtrics site where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics.
In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
Immune-inflammatory diseases are a class of conditions with high prevalence that severely impact the quality of life. Current treatment strategies include immunosuppressants, glucocorticoids, and monoclonal antibodies. However, these approaches have certain limitations, such as poor membrane permeability, immunogenicity, and the requirement for injection in large molecule drugs. Small molecule compounds, on the other hand, suffer from issues like poor selectivity, inability to inhibit non-enzymatic functions, and biological compensation. These factors constrain the effectiveness of current therapeutic strategies in immune-inflammatory diseases. As a novel small molecule drug development technology, proteolysis-targeting chimeras (PROTACs) regulate protein levels by inducing interactions between target proteins and E3 ubiquitin ligases, leading to the selective degradation of target proteins. This technology has already shown promising therapeutic effects in the treatment of immune-inflammatory diseases. This review aims to comprehensively summarize the application of PROTAC technology in the field of immune inflammation and provide insights into its potential in treating immune-inflammatory diseases.
Participants receive SI-B003 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Patients will receive instructions on performing the seven sets of frozen shoulder exercises mentioned earlier. The APP intervention group will be guided through the exercises using the mobile app. Each set of exercises will involve 10 repetitions, and it is recommended to perform four sessions per day.
PURPOSE:To provide a platelet coagulation inhibiting agent containing a specific enone derivative, effective in remarkably suppressing platelet coagulation action induced by arachidonic acid, ADP and collagen and useful as a preventive for thrombosis and cancer metastasis. CONSTITUTION:The enone derivative of formula I [(R)<m> is 3,4-dihydroxy or 3,4-diethoxycarbonyloxy; R is 1-10C alkyl] is used as a platelet coagulation inhibiting agent. The compound of formula I has strong platelet coagulation inhibiting action and can be used as a preventive for diseases caused by the coagulation of platelet, especially myocardial infarction, ischemic fit after cerebral hemorrhage and thrombosis such as cerebral infarction. It can be also used as a preventive for metastasis of cancer. Dose: about 30-60mg/day. The compound of formula I can be produced by the condensation reaction of the compound of formula II with the compound of formula III followed by deprotection reaction and optional protective group-introducing reaction.
Disulfide proteins showed mitigated allergenicity and increased digestibility by pepsin following reduction by thioredoxin. The sulfhydryl groups newly formed on reduction by thioredoxin (at 4° C.) or dithiothreitol (DTT) (at 55° C.) were blocked with a physiological disulfide, such as cystamine or oxidized glutathione (GSSG) to obtain stable forms of the disarmed allergen. When derivatized with cystamine, BLG was separated from its oxidized and reduced forms on non-reducing SDS-PAGE and appeared to lack sulfhydryl groups. Although less effective GSSG, gave similar results. Allergenicity of the two derivatives was compared with that of the oxidized, reduced and reoxidized forms of BLG by skin testing dogs from a colony sensitized to cow's milk. Both the cystamine and GSSG derivatized BLG showed decreased allergenicity and increased sensitivity to pepsin as compared to controls. The reoxidized form resembled the derivatives in having lower allergenicity. The thioredoxin- and DTT-reduced forms showed hypoallergenic, hyperdigestible properties, most effectively when the reduced proteins were heated at 55° C. Whole milk subjected to these procedures showed results similar to those obtained with pure BLG. Other proteins are similarly stabilized. Stable forms of such disarmed, hypoallergenic and hyperdigestible disulfide protein allergens or just hypoallergenic or just hyperdigestible protein allergens are useful in foods as well as clinical preparations.
NEW MATERIAL:A protein (molecular weight, 55,000-140,000 by two-dimensional electrophoresis; isoelectric point, 4.5-5.8). USE:Agent for the remedy and diagnosis of human and animal tumor, cancer and cerebroneurosis. PREPARATION:An animal cell (e.g. neuroblastoma N-18 strain of mouse- originated cell, leiomyoid cerebroma BC3H1 strain, pheochromocytoma PC12 strain as a rat-originated cell, human fatal brain Flow 3,000 strain, etc.) is cultured in proper culture liquid or serum, or is proliferated in an aminal body. The proliferated cells are collected in a mass and homogenized to extract the protein, and the proteins are separated from each other and purified by gel- filtration, ion-exchange chromatography, etc. The protein acts as an essential factor or promotion substance for the growth of tissue cell of cerebroneural system. The effect can be exhibited by applying the protein to a living body. It is also useful as a marker for various tumors.
No carcinogenesis or impairment of fertility studies have been carried out with levalbuterol tartrate. However, racemic albuterol sulfate has been evaluated for its carcinogenic potential and ability to impair fertility. 

In a 2-year study in Sprague-Dawley rats, racemic albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at, and above, dietary doses of 2 mg/kg/day (approximately 30 times the maximum recommended daily inhalation dose of levalbuterol tartrate for adults on a mg/m2 basis and approximately 15 times the maximum recommended daily inhalation dose of levalbuterol tartrate for children on a mg/m2 basis). In another study, this effect was blocked by the coadministration of propranolol, a nonselective beta-adrenergic antagonist. In an 18-month study in CD-1 mice, racemic albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg/day (approximately 3800 times the maximum recommended daily inhalation dose of levalbuterol tartrate for adults on a mg/m2 basis and approximately 1800 times the maximum recommended daily inhalation dose of levalbuterol tartrate for children on a mg/m2 basis). In a 22-month study in the Golden hamster, racemic albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 50 mg/kg/day (approximately 500 times the maximum recommended daily inhalation dose of levalbuterol tartrate for adults on a mg/m2 basis and approximately 240 times the maximum recommended daily inhalation dose of levalbuterol tartrate for children on a mg/m2 basis). 

Levalbuterol HCl was not mutagenic in the Ames test or the CHO/HPRT Mammalian Forward Gene Mutation Assay. Levalbuterol HCl was not clastogenic in the in vivo micronucleus test in mouse bone marrow. Racemic albuterol sulfate was negative in an in vitro chromosomal aberration assay in CHO cell cultures. 

Reproduction studies in rats using racemic albuterol sulfate demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg/day (approximately 750 times the maximum recommended daily inhalation dose of levalbuterol tartrate for adults on a mg/m2 basis).
Gastrointestinal endoscopy is performed as standard for the diagnosis of many gastrointestinal diseases. During gastrointestinal endoscopy, sedoanalgesia is applied to relieve patients' pain and increase patient comfort. Anesthetic drugs used for sedoanalgesia may cause respiratory depression and hypoxia in patients. Hypoxia resulting from hypoventilation in patients is responsible for many events, including coronary ischemia. During these procedures, patients should be given oxygen support to reduce the incidence of hypoxia. The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices. Our study will show us which method is more beneficial in preventing hypoxia and other side effects, providing comfort for the doctor performing the procedure and for the patient undergoing the procedure. This study aimed to compare the efficacy and procedural performance of two different airway devices (Wei Nasal Jet Tube vs Nasal Cannula Oxygen Support) in Gastrointestinal Endoscopy
PURPOSE OF REVIEW: The purpose of this review is to summarize the recent literature relating to viral, fungal and bacterial infections and their interactions within the sinonasal tract in the past 18 months.
RECENT FINDINGS: Coronavirus disease 2019 (COVID-19)-associated olfactory dysfunction (OD) is variant dependent. Magnetic resonance imaging studies have found greater olfactory cleft opacification and higher olfactory bulb volume in post-COVID-19 OD. Olfactory training remains the mainstay of treatment, while platelet-rich plasma injections and ultramicronized palmitoylethanolamide and luteolin combination oral supplementation have shown early promise.Consensus statements on paranasal sinus fungal balls and acute invasive fungal sinusitis have been released.Studies on the nasal microbiome have reported Staphylococcus and Corynebacterium as the most abundant genera, with higher levels of Staphylococcus and Corynebacterium being found in patients with chronic rhinosinusitis (CRS) and healthy individuals respectively. However, there is conflicting evidence on the significance of biodiversity of the nasal microbiome found in CRS versus healthy patients.
SUMMARY: While the peak of the COVID-19 pandemic is behind us, its sequelae continue to pose treatment challenges. Further studies in OD have implications in managing the condition, beyond those afflicted post-COVID-19 infection. Similarly, more research is needed in studying the nasal microbiome and its implications in the development and treatment of CRS.
The present invention relates to a traditional Chinese medicine preparation for treating chronic erosive gastritis and enteritis, which belongs to the technical field of medicine and is used for solving the problem that chronic erosive gastritis and enteritis are not cured after long-term treatment. The traditional Chinese medicine preparation has the scheme: the traditional Chinese medicine preparation uses dandelion, heartleaf houttuynia herb, hedgehog hide and tree of heaven ailanthus bark as raw materials; the raw materials are manufactured into pills through proportion, processing, pulverization and mix. The traditional Chinese medicine preparation clears away heat and toxic material, eliminates swelling, alleviates pain, discharges damp-heat and foul air and promotes tissue regeneration. After perennial clinical practice grope, a simple prescription is varied, and the relationship of medicinal ingredient dose and medicine compatibility is determined to a set of prescriptions prepared from pure Chinese herbs; the rescriptions are manufactured into a Chinese patent medicine for treating chronic erosive gastritis and enteritis, and a satisfactory effect is received. The present invention has the characteristics of outstanding curative effect and both manifestation and root cause of disease treatment; clinical observation shows that the effectual rate reaches more than 89%, and the present invention has a certain therapeutic effect on patients with stomach cancer and intestinal cancer. The traditional Chinese medicine preparation of the present invention has the advantages of abundant medicine source, simple manufacture, low cost and convenient administration.
The invention relates to an echinococcus granulosus EgFABP-Eg95 polypeptide and preparation and application of recombinant brevibacterium vaccine thereof. The invention provides the echinococcus granulosus EgFABP-Eg95 polypeptide, an encoding gene of the polypeptide and an antibody of the polypeptide. The invention further provides a genetically engineered host strain which comprises the encoding gene of the echinococcus granulosus EgFABP-Eg95 polypeptide. The invention also provides two kinds of vaccines which are applicable to the intermediate host and the definitive host of echinococcosis. The brevibacterium vaccine recombined by the echinococcus granulosus EgFABP-Eg95 polypeptide of the invention has relatively high resistance, high-temperature resistance, high- salinity resistance, acid resistance, alkali resistance and dryness resistance, so that the recombinant brevibacterium vaccine can be easily used as feed additive. The recombinant brevibacterium vaccine can stimulate responses of hosts Thi and Th2, therefore protecting intermediate hosts, such as human, cattle, sheep and the like from infection of ovum. The recombinant brevibacterium vaccine can also be used as vaccine of canine definitive host, thus promoting discharge of imago to eliminate the infection origin of echinococcosis.
Apply lidocaine patch 5% to intact skin to cover the most painful area. Apply the prescribed number of patches (maximum of 3), only once for up to 12 hours within a 24 hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner (see HANDLING AND DISPOSAL). Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination. 

If irritation or a burning sensation occurs during application, remove the patch(es) and do not reapply until the irritation subsides. 

When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. 

Lidocaine patch 5% may not stick if it gets wet. Avoid contact with water, such as bathing, swimming or showering.
PURPOSE: A bisphosphonate compound is provided to suppress bond of PTP-1B(Protein Tyrosine Phosphate 1B) and IR(Insulin Receptor), to treat insulin secretion in pancreatic islet, and to be used as a preventive and therapeutic agent for type 2 diabetes. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes contains zoledronate or a pharmaceutically acceptable salt thereof as an active ingredient. The diabetes is type 2 diabetes. Zoledronate or a pharmaceutically acceptable salt is administered to an individual in an amount of 0.001-0.2 mg/day, 0.15 mg/day, or 0.1 mg/day to prevent or treat diabetes. Zoledronate or a pharmaceutically acceptable salt is used by oral, intravenous, subcutaneous, and intrarectal administration. Zoledronate or a pharmaceutically acceptable salt suppresses bond of PTP-1B with IR. [Reference numerals] (AA,FF) Insulin acceptor; (BB) Non-activated type; (CC) Insulin; (DD) Pancreas; (EE) Activated type; (GG) Substrate phosphorylation; (HH) Sugar absorption
On review of our experience with treatment for brain metastases since 2009, we have treated over 100 patients with 6 or more metastases in a single radiosurgery session. In the past year and a half (2015-16) there have been approximately 50 patients treated with six or more metastases, indicating that there has been a shift in management of intracranial metastatic disease with increasing preference for radiosurgery despite the presences of greater metastatic burden. The phase I component will accrue 7-15 patients at each dose cohort until the MTD is determined. Once the MTD is reached, the phase II component will commence with a total of 50 patients total enrolled at the MTD, with a study time of 3 years. The primary endpoint of the phase I component is toxicity. The primary endpoint of the phase II component is the change in neurocognitive function, defined by a decline in the Hopkins Verbal Learning Test- Revised delayed recall. Data from the WBRT-alone arm of the PCI-P-120-9801 phase III trial evaluating WBRT plus motexafin gadolinium demonstrated a 30% mean relative decline in the HVLT-R delayed recall score from baseline to 4 months, with a standard deviation of 41% 9,10. More recently, in patients treated with SRS alone for 1-3 metastases versus SRS plus whole brain radiotherapy, the 4-month rates of HVLT-R delayed recall deterioration were 6% and 22% for the SRS alone arm and SRS + whole brain radiotherapy arm, respectively. Given the greater intracranial burden of disease, we estimate the mean relative decline in HVLT-R delayed recall to be intermediate between SRS alone for 1-3 metastases and whole brain radiotherapy. We predict that after SRS for multiple metastases the mean relative decline in delayed recall as 15%, an improvement over the historical control of whole brain radiotherapy alone which had a mean relative decline in HVLT-R delayed recall of 30%.